Biomarking PTEN

Researchers from the University of California at Los Angeles and colleagues have identified a biomarker that may prove helpful in selecting likely responders to participate in clinical trials of PTEN inhibitors to treat cancer. The study, published recently in the Proceedings of the National Academy of Sciences, showed an inverse correlation between insulin-like growth factor binding protein 2 (IGF-BP2) and PTEN, a tumor suppressor gene

Read the full 650 word article

How to gain access

Continue reading with a
two-week free trial.